Hypoxia induces macrophage polarization and re-education toward an M2 phenotype in U87 and U251 glioblastoma models

Marine M Leblond1,2,3,4, Aurélie N Gérault1,2,3,4, Aurélien Corroyer-Dulmont1,2,3,4, Eric T MacKenzie1,2,3,4, Edwige Petit1,2,3,4, Myriam Bernaudin1,2,3,4, and Samuel Valable1,2,3,4,*

1CNRS; UMR6301-ISTCT; CERVOxy Group; GIP CYCERON; 8d Henri Becquerel; Caen Cedex, France; 2Université de Caen Basse-Normandie; Caen, France; 3CEA; DSV/I2BM; Caen, France; 4Normandie Université; Caen, France

Keywords: brain tumor, hypoxia, M2 macrophages, polarization, re-education

Abbreviations: Arg1, arginase-1; CAIX, carbonic anhydrase IX; GBM, glioblastoma; iNOS, inducible nitric oxide synthase; MΦ, macrophage; NO, nitric oxide; O2, oxygen; PIMO, pimonidazole; ptO2, tissue partial pressure of oxygen; SDF-1α, stromal cell-derived factor 1 α; SN, supernatant; TC, tumor core; TS, tumor shell; [18F]-FMISO, 3-[18F]-fluoro-1-(2-nitro-1-imidazolyl)-2-propanol.

Introduction

GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1 GBM are the most frequent and aggressive primary brain tumors of the adult. Despite surgery, radiotherapy and chemotherapy, the median survival of patients is dismally low.1

Hypoxia is a common feature of solid tumors, particularly in glioblastoma (GBM), and known to be a poor prognosis factor in GBM patients. The growth of GBM is also associated with a marked inflammation partially characterized by an accumulation of macrophage (MΦ) of the M2 phenotype. However, the transition between M1 MΦ (antitumoral) and M2 MΦ (protumoral) phenotypes is a dynamic process. We made the assumption that oxygen (O2) availability could be a major regulator of this transition and that the intratumoral O2 gradient is of importance. We evaluated, in vivo, the impact of hypoxia on MΦ tropism and polarization in two models of human GBM, well differentiated by their degree of hypoxia. MΦ migration in the tumor was more pronounced in the more hypoxic tumor of the two GBM models. In the more hypoxic of the models, we have shown that MΦ migrated at the tumor site only when hypoxia takes place. We also demonstrated that the acquisition of the M2 phenotype was clearly an evolving phenomenon with hypoxia as the major trigger for this transition. In support of these in vivo finding, M0 but also M1 MΦ cultured in moderate or severe hypoxia displayed a phenotype close to that of M2 MΦ whose phenotype was further reinforced by severe hypoxia. These results highlight the role of hypoxia in the aggressiveness of GBM, in part, by transforming MΦ such that a protumoral activity is expressed.

GBM are highly heterogeneous tumors which can be considered as a multi-compartmental system divided into the tumor cells, the vasculature and the microenvironment. Commonly, the tumor microenvironment is a hypoxic milieu in which cell types other than tumoral cells are observed inside or close to the tumor mass such as fibroblasts, stromal cells and multiple components of the immune system.2,3 Hypoxia, formally defined as an inadequacy between O2 supply and demand, is the consequence, in tumor, of a functionally inappropriate vascularization, and/or irregular blood flow relative to the high-proliferation rate of tumor cells. Hypoxia is one main feature of GBM relative to lower grade glioma4 with a tissue partial pressure of oxygen (ptO2) demonstrated to be inferior to 10 mmHg in the tumor core (TC).5,6 Hypoxia triggers many intracellular modifications allowing adaptation to the low O2 availability as well as the potentiation of the infiltration and migration of tumor cells.7 Hypoxia is known to induce angiogenesis and to promote resistance to therapies8 and has been shown to be an independent factor for a reserved prognosis in GBM patients.9

In solid tumors, MΦ are the most abundant infiltrative inflammatory cells present in and around tumors.10 Circulating monocytes can enter tumors11 under the effect of chemokines synthetized by several cell types, including the cancerous cells themselves.12 Once entered the tissues, monocytes differentiate into MΦ under the influence of cytokines, and accumulate in specific tumor regions, such as hypoxic/necrotic areas.12 In GBM, MΦ can migrate in the tumor13,14 and have been described as the most abundant infiltrative inflammatory cells.2,15 More interestingly, it has been demonstrated that the number of MΦ is inversely correlated with the survival of GBM patients.16

© Marine M Leblond, Aurélie N Gérault, Aurélien Corroyer-Dulmont, Eric T MacKenzie, Edwige Petit, Myriam Bernaudin, and Samuel Valable
*Correspondence to: Samuel Valable; Email: valable@cyceron.fr
Submitted: 03/13/2015; Revised: 05/22/2015; Accepted: 05/24/2015
http://dx.doi.org/10.1080/2162402X.2015.1056442
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
Moreover, once in the tissue, MΦ are likely to undergo a rapid phenotype switching affected by local environmental signals. MΦ can be polarized into principally two main distinct phenotypes, M1 or M2, which have been respectively proposed to either restrict or promote tumor development.\textsuperscript{17,18} M1 MΦ, characterized by the expression of the inducible type of nitric oxide synthase (iNOS) are pro-inflammatory MΦ implicated in an antitumor activity, especially by their phagocytic properties and their capacity to activate pro-inflammatory syntheses. MΦ are polarized into M1 phenotype by the presence of diverse pro-inflammatory cytokines, such as interferon-γ (IFN-γ), or microbial molecules, such as lipopolysaccharide (LPS).\textsuperscript{19} On the contrary, M2 MΦ, essentially characterized by a potent arginase-1 (Arg1) activity, are anti-inflammatory MΦ not only known to promote tumor development by tissue remodeling, cell proliferation and immunoregulation but also by promoting angiogenesis.\textsuperscript{20} MΦ can acquire an M2 phenotype by the presence of several anti-inflammatory molecules such as the interleukins: IL4, IL10 and/or IL13.\textsuperscript{19} The phenotype of MΦ present in tumors is not yet fully established but it seems to be a dynamic process. It has been hypothesized that M1 MΦ are found at the initiation of tumor development and that MΦ are polarized into an M2 phenotype along with the growth of the tumor.\textsuperscript{21,22} In the instance of GBM, a recent study has demonstrated that the presence of M2 MΦ increases with glioma grade and that an inverse relationship exists between patient survival and the concentration of M2 MΦ.\textsuperscript{23}

Despite these results, the factors responsible for MΦ migration and polarization in GBM remain obscure. However, MΦ are likely to have an important impact on tumor development. For example, it has been recently shown that the re-education of M2 MΦ to M1 MΦ has a marked beneficial impact on glioma growth.\textsuperscript{24}

Hypoxia has been proposed to be at the origin of the migration of MΦ into the tumor.\textsuperscript{1,2} Consistent with this, the most hypoxic areas of numerous solid tumors are known to have a pronounced congregation of M2-like MΦ.\textsuperscript{25-27} Hypoxia has also been suggested to be a possible cause of MΦ polarization. Indeed, hypoxia may induce the synthesis of protumoral molecules by the tumor cells which, in turn, would promote MΦ to polarize into the M2 phenotype.\textsuperscript{28-30} Moreover, \textit{in vitro} studies have also implied that hypoxia may directly act on MΦ to induce a polarization into an M2 phenotype.\textsuperscript{30,31} However, up until now, the detailed relationship between hypoxia and the M1 to M2 migration has never been formally analyzed \textit{in vivo} and warrants an in-depth investigation. Using robust and pertinent models of GBM, previously shown to develop severe hypoxia\textsuperscript{32} as such that observed in patients,\textsuperscript{33} we evaluated whether GBM hypoxia, in addition to its well described effect on the infiltration of MΦ, could affect the acquisition of an M2 phenotype.

In conclusion, even if hypoxia is assumed to polarize MΦ into the M2 form, the intrinsic ability of hypoxia to drive a conversion of M1, suspected to be present at the onset of GBM development, to M2 has never been tested, to the best of our knowledge. Accordingly, we analyzed the impact of hypoxia to re-educate M1 MΦ into the M2 phenotype.

### Results

#### Hypoxia-related MΦ migration

To determine whether hypoxia influences MΦ migration in GBM, we used two models of human GBM, U87 and U251, known to be non-hypoxic and severely hypoxic, respectively.\textsuperscript{32} CD68 immunostaining was performed to visualize the MΦ/microglial cells present in the tumor. 23 ± 5% of CD68\textsuperscript{+} cells in the tumor of the hypoxic U251 model were observed compared to only 12 ± 6% in the less hypoxic tumor implanted with the U87-MG cells (Fig. 1Aa and Ab). CD14 immunostaining was then used to differentiate MΦ (CD68\textsuperscript{+}/CD14\textsuperscript{+}) from microglia (CD68\textsuperscript{+}/CD14\textsuperscript{−}).\textsuperscript{34} 21 ± 2% of CD68\textsuperscript{+} cells were also CD14\textsuperscript{+} in the U87 tumor compared to 58 ± 29% in the U251 tumor (Fig. 1Aa). To evaluate whether this migration was essentially hypoxia-dependent and not intrinsic to the tumor cells themselves, we examined the MΦ migration in U251 tumor prior to the development of hypoxia. The [\textsuperscript{18F}]-FMISO \textmu PET analysis, performed to estimate the level of hypoxia, showed no [\textsuperscript{18F}]-FMISO uptake in the relatively small tumor but, in contrary, a sustained [\textsuperscript{18F}]-FMISO uptake in the later stage of tumor development (Fig. 1Ba). This was also confirmed with the carbonic anhydrase IX (CAIX) (Fig. 1Bb) and the stromal cell-derived factor 1 α (SDF-1α) immunostainings (Fig. S1A), known to be upregulated in hypoxia (Fig. S1B).\textsuperscript{35,36} Immunostainings showed that 67 ± 28% of CD68\textsuperscript{+} cells were also CD14\textsuperscript{+} in the hypoxic tumor while only 9 ± 13% were found in the pre-hypoxic tumor (Fig. 1Bc and Bd). When computing the number of MΦ (CD68\textsuperscript{+}/CD14\textsuperscript{+}) as a function of tumor volume, a sigmoidal relationship was observed (data not shown). These results indicate that MΦ are found in the U251 tumor at the hypoxic state. With the hypoxic U251 tumors, we also confirmed that the accumulation of MΦ occurs mainly in the hypoxic regions (Fig. S1C) which can be inferred from the SDF-1α expression marginal to the hypoxic core (Fig. S1D).

#### GBM oxygenation-related MΦ polarization

We then analyzed the relationships between hypoxia and MΦ polarization. Accordingly, M1 and M2 MΦ were differentiated by iNOS and Arg1 immunostaining, respectively. In the U87 tumor, iNOS staining co-localized with the CD68 signal (31±13% were CD68\textsuperscript{+}/iNOS\textsuperscript{+}) while Arg1 staining was not detected (2 ± 2% were CD68\textsuperscript{+}/Arg1\textsuperscript{+}) (Fig. 2A). In the hypoxic U251 tumor, no iNOS signal was apparent (0.6 ± 0.4% were CD68\textsuperscript{+}/iNOS\textsuperscript{+}) but the Arg1 signal co-localized with CD68 (55 ± 31% were CD68\textsuperscript{+}/Arg1\textsuperscript{+}) (Fig. 2C). MΦ polarization was also determined in the pre-hypoxic U251 tumor to ascertain that the presence of M2 MΦ is not intrinsic to the GBM cell types themselves but rather may be a function of O\textsubscript{2} availability. No iNOS staining was visualized (1.5 ± 2% were CD68\textsuperscript{+}/iNOS\textsuperscript{+}) but the signal for Arg1\textsuperscript{+}, though detected, was not significant (10 ± 16% were CD68\textsuperscript{+}/Arg1\textsuperscript{+}) (Fig. 2B).

Although M2 MΦ were found in the hypoxic tumor, the question that arises is whether M2 MΦ aggregation has a localization specific to the most hypoxic areas. The images of the entire volume of the hypoxic U251 tumor were taken and were divided
into two regions: the TC known to be severely hypoxic and the tumor shell (TS) known to be less hypoxic and more vascularized (Fig. 3A). On this basis, iNOS and Arg1 stainings were localized and compared to that of the CD68 signal. The CD68 staining was present in the TC but also in the TS of the U251 tumor (Fig. 3B and C). In the whole tumor, iNOS signal was observed in the TS (19 ± 9% were CD68+/iNOS–) (Fig. 3B). Arg1 signal was preferentially present in the TC (63 ± 28% were CD68+/Arg1+), more particularly around pseudopalisades (Fig. 3C), and only localized in pimonidazole positive areas of this tumor (Fig. 3D). These results indicate not only that the MΦ present at the shell of this tumoral model are M0 (CD68+/iNOS–/Arg1–) but also M1 MΦ (CD68+/iNOS+/Arg1+), though the MΦ detected in the hypoxic areas present an M2 phenotype (CD68+/iNOS–/Arg1+).

Our in vivo result suggest that hypoxia is responsible for the acquisition of an M2 phenotype. However, hypoxia may drive this polarization by also acting on tumor cells. To test this latter hypothesis, we performed in vitro studies, as described below.

Effect of hypoxia-exposed GBM cells supernatants on M0 MΦ polarization
U87-MG and U251 cells were cultured in 1% O₂ for 24h and the
supernatant (SN) was transferred onto M0 MΦ for 24h (Fig. 4). No changes in M0 MΦ morphology were observed when the SN from U87-MG and U251 cells either in normoxia or in hypoxia was applied (Fig. 4A). In parallel, no significant effects on the expression of iNOS and Arg1 mRNA were observed in M0 MΦ cultured either with SN from U87-MG or U251 cultured in 1% or 0.2% O2 (Fig. 4B). Functionally, no significant changes in NO production were observed in M0 MΦ cultured either with SN from U87-MG or U251 cultured in 1% or 0.2% O2 for 24 h (Fig. 4C). Moreover, no changes in Arg1 activity were observed when M0 MΦ were cultured with SN from U87-MG and U251 cells cultured in 1% O2. However, M0 MΦ cultured with SN from U251 in 0.2% O2 had a significant increase in Arg1 activity (36 ± 7 μg urea/h per 10^6 cells), which was not observed with the U87-MG SN, compared to M0 MΦ cultured with SN from U251 in normoxia (23 ± 4 μg urea/h per 10^6 cells) (Fig. 4C). The cytokine profile of the U87-MG and U251 cells cultured in hypoxia failed to show any change in the expression of IFNγ and IL4 both well-known to induce the polarization of M1 and M2 MΦ, respectively (Fig. S2). These results indicate that severe hypoxia applied to tumor cells induced Arg1 activity in M0 MΦ, only in one GBM cell type, and independently of IFNγ and IL4 productions. However, to conclude on the hypoxic cytokine production in GBM cells, a large genomic approach would be of need to evaluate. Consequently, we postulated that hypoxia could directly influence MΦ polarization.

**Hypoxia polarizes M0 toward M2 MΦ independently of GBM cells**

M0 MΦ were directly cultured at different degrees of hypoxia over different time periods (Figs. 5 and S3). After 24 h in 1% or
0.2% O2, M0 MΦ presented a cell morphology similar to that of M2 MΦ (Fig. 5A). Of note is that iNOS mRNA levels increased in M0 MΦ after 24 h in 1% O2, at a level significantly less than M1 MΦ (about 70 compared to 105 times greater, respectively, when normalized to M0 MΦ in normoxia) but not significantly different from M2 MΦ. M0 MΦ cultured in 0.2% O2 for 24 h did not express iNOS mRNA as M2 MΦ (Fig. 5B). In the contrary, Arg1 mRNA was clearly expressed in M2 MΦ and M0 MΦ cultured in 1% or 0.2% O2 when normalized to M0 MΦ in normoxia (between 102 to 103 times greater) but not in M1 MΦ (Fig. 5B). Moreover, the increase in exposure time decreased the iNOS mRNA expression and increased the Arg1 mRNA expression in M0 MΦ (Fig. S3A). These results show that M0 MΦ cultured in hypoxia increase the expression of Arg1 mRNA but not iNOS mRNA. Functionally, NO was produced in M1 MΦ (230 ± 61 μM of NO per 10^6 cells) and was significantly different from the level of M2 MΦ and M0 MΦ cultured in 1% or 0.2% O2 (24 ± 2, 26 ± 3 and 23 ± 5 μM of NO per 10^6 cells, respectively). However, M0 MΦ cultured after 24h in 1% or 0.2% O2 had Arg1 activities not significantly different from M2 MΦ (33 ± 1, 62 ± 12 and 43 ± 8 μg urea/h per 10^6 cells, respectively) (Fig. 5C). Furthermore, the longer the time of exposure of hypoxia increased the Arg1 activity but not the NO production in M0 MΦ (Fig. S3B). These results strengthen the possibility that hypoxia directly polarizes M0 into M2 MΦ with a more efficient effect than through GBM cells.

**Hypoxia reinforces the M2 phenotype and re-educates M1 MΦ toward an M2 phenotype**

We have previously shown that M2 MΦ are found in hypoxic tumors and that hypoxia may drive the polarization of M0 MΦ. However, M2 MΦ could arise from the re-education of resident M1 MΦ in the tumor.

After having demonstrated that hypoxia is more potent to induce the M2 phenotype directly than via GBM cells, we therefore studied the question whether
Hypoxia could also directly re-educate M1 into M2. MΦ were pre-polarized to either M1 or M2 phenotype for 24 h and then cultured in 1% or 0.2% O2 for different times (Fig. 6 and Fig. S4). Morphologically, no changes were observed when M2 MΦ were cultured in 1% O2 for 24 h, but M1 MΦ seemed smaller and more readily defined under phase contrast after hypoxia exposure (Fig. 6A). At the transcriptional level (Fig. 6B), no significant changes were detected in M1 MΦ cultured in 1% O2 for 24 h. However, a significant decrease in iNOS mRNA expression were observed in M1 MΦ cultured in 0.2% O2 (about 60 times greater compared to M0 in normoxia) compared to M1 MΦ in normoxia (about 10^5 times greater), with a level close to that of M2 MΦ in normoxia (about 30 times greater). Arg1 mRNA expression was increased in M1 MΦ cultured in 0.2% O2 (about 500 times greater), at a level close to that of M2 MΦ (about 10^5 times greater). Exposure of M2 MΦ to 1% or 0.2% O2 did not induce significant changes in the expression of Arg1 mRNA (Fig. 6B). Furthermore, the increase in the time the cells were exposed to hypoxia, decreased the iNOS mRNA expression in M1 MΦ and increased the Arg1 mRNA expression in M2 MΦ (Fig. S4A). Functionally, NO production in M1 MΦ significantly decreased with the decrease in O2 level (200 ± 35, 122 ± 30 and 84 ± 17 μM of NO for 10^6 cells in M1 MΦ in normoxia, 1% and 0.2% O2, respectively) (Fig. 6C). In the contrary, Arg1 activity increased in M1 MΦ cultured in hypoxia (38 ± 7 and 46 ± 8 μg urea/h per 10^6 cells in M1 MΦ in 1% and
0.2% O₂, respectively) at a level not significantly different from M2 MΦ (88 ± 47 μg urea/h per 10⁶ cells). A significantly increase in Arg1 activity was observed in M2 MΦ after 24 h of 0.2% O₂ (192 ± 28 μg urea/h per 10⁶ cells) compared to normoxia (Fig. 6C). Moreover, the Arg1 activity increased in M2 MΦ with longer the time of exposure to hypoxia (Fig. S4B). These results show that hypoxia seems to decrease iNOS mRNA expression/NO production in M1 MΦ and to reinforce M2 markers in M2 MΦ. Furthermore, M0 (Fig. S5A), M1 and M2 (Fig. S5B) MΦ cultured in 1% or 0.2% O₂ and then re-oxygenated in 20% O₂ for 24 h did not show a difference of iNOS and Arg1 activity compared to MΦ maintained in hypoxia. These results indicates that re-oxygenation fails to change the MΦ phenotype acquired in hypoxia.
**Discussion**

Recent reports have demonstrated that hypoxia plays an important role in tumor development, treatments resistance and tumor inflammation. The inflammatory microenvironment is essential for tumoral development, particularly MΦ, markedly present in GBM. In this study, we have shown, in vivo, in a model of GBM that progressively evolves toward severe hypoxia, and in vitro, that GBM hypoxia is responsible for MΦ polarization, for a re-education of M1 MΦ toward an M2 phenotype and for fine-tuning the M2 phenotype.

Numerous studies have tried to correlate MΦ with hypoxia and it seems, as noted in the present investigation, that this relationship may be model or cell lines dependent. It should be underlined that the hypoxic signal, observed in the present study, seems to be the most important trigger for MΦ migration as well as for polarization rather than the cell type. We observed that MΦ were the most abundant in the U251 tumor that best replicates the hypoxic characteristics of human GBM. It is not...

---

**Figure 6.** Effect of hypoxia on MΦ re-education. (A) Phase contrast microscopy of M0, M1 and M2 MΦ in normoxia (20% O2) or in 1% O2 for 24 h. Scale bar: 20 μm. iNOS and Arg1 mRNA relative expressions (compared to M0 MΦ in normoxia) (B) and NO concentration (μM per 10⁶ cells) and Arg1 activity (μg urea/h per 10⁶ cells) (C) in M1 and M2 MΦ in normoxia (20% O2) or in 1% or 0.2% O2 for 24 h; Data were represented as the mean ± SD, n = 3 per group and per time. Statistical significance was achieved when p < 0.05 (*), otherwise it was not significant (NS).
unlikely that the two cell lines we employed may produce different cytokines and/or chemokines. Accordingly, we analyzed the evolution of MΦ migration as a function of tumoral growth with increasingly severe hypoxia. We demonstrated that this MΦ migration is oxygen-dependent. Few MΦ were observed at the early phase of U251 tumor development when hypoxia was undetectable. This oxygen-dependent phenomenon could explain the increase in MΦ numbers with increasing grade of gliomas, and is consistent with the observation that pcO₂ values also fall as the glioma grade increases. Altogether, these data indicate that MΦ can accumulate in hypoxic areas of GBM and only by the presence of hypoxia.

Based on publications that have studied the relationship between the number of M2 MΦ and the grade of glioma, we have examined the possibility that hypoxia may also drive the acquisition of an M2 phenotype. Indeed, the MΦ polarization in a tumor is a relatively recent and not yet fully established concept. Here, we have shown marked differences between the two different models of glioma employed. In the early development of the U251 tumor, a time at which hypoxia had not yet developed, the proportion of M1 or M2 markers were very low. In contrast, in the late phase of the U251 tumor, MΦ present at the less hypoxic and more vascularized TS, or margin, were both M0 and M1 MΦ as described in mammary tumors, the only MΦ present in the highly hypoxic TC exhibited discriminatory factors for the M2 phenotype. This study demonstrate a pronounced transformation of MΦ, concomitant to the hypoxic shift, and this within the evolution of a single type of tumor.

After having shown the association between the normoxic/hypoxic transition and the acquisition of the M2 phenotype, the next question was to know whether these M2 MΦ were derived from (i) M0 MΦ, (ii) newly arrived M2 MΦ or (iii) re-educated from M1 MΦ as initially suspected. Although the effect of hypoxia on MΦ gene expression in tumor development has been studied, no one has described the direct effect of the O₂ gradient on MΦ polarization. We cultured M0 MΦ in moderate (1% O₂) and severe hypoxia (0.2% O₂) to mimic the O₂ gradient observed in vivo. Despite that several studies have demonstrated that MΦ polarization toward an M2 phenotype was induced by hypoxic tumor cells, we have shown that this hypoxia effect is independent on GBM cells. Indeed, when we performed the co-culture experiments, the production of urea was observed only with one GBM cell type and the amount of urea was no more than 36 ± 7 μg urea/h per 10⁶ cells. These results speak about a direct effect of hypoxia on MΦ polarization. Furthermore, we observed that the more severe the hypoxia, the more importantly the M0 MΦ expressed M2 MΦ markers. These results could explain our in vivo observations in which circulating monocytes enter the tumor as M0 MΦ and then acquire M2 markers with decreased O₂ levels and consequently become exclusively M2 MΦ in parallel with their accumulation in the hypoxic zones within the tumor. Factors responsible for this hypoxia-dependent MΦ polarization could be the hypoxia inducible factors, HIF-1α and HIF-2α. It has been suggested that HIF-1α was stable in M1 MΦ while HIF-2α was stabilized in M2 MΦ but also that HIF-1α was stable in acute hypoxia compared to HIF-2α which was stable under chronic hypoxia. Thus, HIF-2α seems to be involved in the establishment of an M2 phenotype under hypoxia but this needs to be demonstrated. A recent study has also indicated that M2 MΦ were promoted by the lactate acid produced by hypoxic tumor cells. Another hypothesis is that hypoxic M2 MΦ could also produce lactic acid which in turn reinforces the M2 phenotype. In this way, it could be interesting to focalize on this pathway and try to inhibit lactic acid production or intracellular transport in cells to inhibit or re-educate M2 MΦ in GBM.

However, as proposed, M2 MΦ may originate from a re-education of M1 MΦ originally present at the initial stage of tumoral development and this re-education would be induced by cytokine stimuli. Here, we hypothesize that hypoxia may directly re-educate M1 MΦ, which has never been assessed in vitro to the best of our knowledge. We demonstrated that the more severe the hypoxia and the more the M1 markers were decreased, the greater the more severe hypoxia. We also observed an augmented expression of M2 markers on M2 MΦ as an inverse function of O₂ availability. These results not only indicate that hypoxia could induce the re-education from antitumoral MΦ toward protumoral MΦ but also that severe hypoxia fine-tunes the protumoral phenotype as already described in lung carcinoma. In this study, we have demonstrated that hypoxia directly differentiates M0 MΦ, but also re-educates M1 MΦ toward an M2 phenotype. These results differ from those of Laoui and coworkers (2014), who demonstrated (in a model of pulmonary carcinoma) that hypoxia is without influence on the polarization of M0 MΦ and the re-education of M1 MΦ. Although various hypotheses could explain this discrepancy, we postulate that a major possibility might be the degree of hypoxia. Indeed, in our study, we clearly show from both in vivo and in vitro experiments that the more pronounced the hypoxia, the more the M2 phenotype is present. In GBM, it has been demonstrated that, even if the median ptO₂ is 7.4 mmHg, the ptO₂ around pseudopalisaded areas is lower than 2.5 mmHg and even attaining near zero in the core. It is in these severe hypoxic (or near anoxic) conditions that we observe the M2 phenotype. In the study from Laoui and colleagues (2014), one might note that the initial ptO₂ was around 6 mmHg in their tumor model, a degree of hypoxia described as being “moderate” in a general review on this subject. Rather than reinforce hypoxia, Laoui and coworkers induced a minor re-oxygenation (from 6 to 10 mmHg), whereas our results show that a complete re-oxygenation of MΦ failed to change the phenotype acquired in hypoxia. Concomitant to the effects of hypoxia-induced changes in the metabolism of glioma cells and also in angiogenesis, the potentiation of a protumoral inflammation should also be considered as an explanation of the results that show that hypoxia is an independent, negative prognostic factor in GBM.

As a conclusion, in our study, we made the assumption that hypoxia should not be considered as a binary process but as a slowly evolving process which may directly drive the acquisition of a protumoral immunity. We used two models of GBM, highly different in terms of oxygenation and benefited from the ability to assess intratumoral hypoxia as a function of time to show that
MΦ migration into the tumor as well as MΦ polarization toward a protumoral phenotype are related to the depth of hypoxia. As the GBM grows, the volume of hypoxia expands and its severity increases, hence the acquisition of the M2 phenotype (Fig. 7). However, up to now, we have been unable to characterize the effects of M2 MΦ in this model.

As large amounts of NO, produced by M1 MΦ, has been demonstrated to induce cell damage and inhibit tumor angiogenesis, several attempts have been made to re-educate protumoral MΦ toward antitumoral MΦ rather than the depletion of MΦ. Our present investigation encourages a combination of these recently developed therapies for GBM with approaches designed to alleviate intratumoral hypoxia to further potentiate the efficacy of available chemotherapeutic agents. For instance, low dose antiangiogenic therapy, low dose irradiation, or hyperoxic gases could all be pertinent strategies to mitigate against the tumoral accumulation of M2 MΦ.

Materials and Methods

GBM cell culture

Human GBM cell lines, U87-MG (ATCC) and U251 (NCI), were cultured in 1 g/L glucose Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma) supplemented with 10% fetal calf serum (Eurobio), 1 mg/mL penicillin/streptomycin (P/S, Sigma) and 2 mM glutamine (Gln, Sigma) at 37°C in wet atmosphere.

Tumor models

Tumor models consist of an orthotopic injection of human GBM cells in athymic rats (200–250 g, Charles River Laboratory). The animal investigations were performed under the current European directive (2010/63/EU). The license to investigate was given to SV (14–55) in authorized housing and laboratories (B14118001) and with the permission of the regional committee on animal ethics (CENOMEXA, 0611-02). The rats were maintained in specific pathogen-free housing and were fed γ-irradiated laboratory food and water ad libitum.

Rats were operated under anesthesia (induction in 5% and maintenance in 2% of isoflurane in 70% NO2/30% O2) and U87-MG and U251 cells were injected (5.10⁴ cells in 3 μL in 2 mM Gln/PBS) in the right caudate-putamen.

Imaging

For all imaging experiments, animals were anesthetized as described above, and maintained in position by ear and tooth bars. Micro-magnetic resonance imaging (μMRI) was performed on a 7 Tesla horizontal magnet (Pharmascan®, Bruker, Germany). Micro positron emission tomography (μPET) was performed on an Inveon PET-CT small animal imaging system (Siemens Healthcare) with the use of the tracer, 3-[18F]-fluoro-1-(2-nitro-1-imidazolyl)-2-propanol ([18F]-FMISO), to detect hypoxia. Imaging protocols are detailed in supplementary data.

Immunohistochemistry

At the end of the protocol, the rats were deeply anesthetized and were transcardially perfused with a 0.2 M phosphate buffer (PB)/4% paraformaldehyde (PFA, Sigma) solution 2 h after the intraperitoneal injection (80 mg/kg) of pimonidazole (Hypoxyprobe Incorporation, USA). The brain was removed and placed in 30% sucrose for 48 h and 30 μm thick freezing microtome sections were realized. Slices were blocked with PBS, 0.5% Triton, 3% BSA (Sigma) for 2 h and then incubated overnight with primary antibodies (Table S1) in PBS, 0.5% Triton, 1% BSA at 4°C. Sections were then incubated with fluorochrome-conjugated secondary antibodies (Table S1) and Hoechst 33342 (Sigma, 10 μg/mL) in PBS solution as described above.

Image analysis

Images were analyzed by in-house macros based on ImageJ software (http://imagej.nih.gov/ij/). MΦ/microglial cell density was determined as the number of positive pixels for CD68 divided by the total tumor area. MΦ density was differentiated from that of microglia by the ratio of CD14 positive pixels to CD68 positive pixels. M1 and M2 MΦ densities were characterized by the number of either iNOS or Arg1 positive pixels, respectively, within the population of CD68 positive pixels.
Bone marrow-derived MΦ culture and activation

Bone marrow was isolated from femora and tibiae of nude mice (20–25 g, Charles River Laboratory) by flushing the bones with 1 mL of Iscove’s Modified Dulbecco’s Media (IMDM, Sigma) containing 60% Fetal Clone II (FCS, Thermo Scientific) and 1 µg/mL P/S (Sigma). The marrow was passed through a 70 µm strainer and MΦ (M0) were selected and cultured in IMDM enriched with 15% FCS, 1 µg/mL P/S, 10 ng/mL recombinant mouse MΦ colony-stimulating factor (M-CSF, Miltenyi Biotec) and 10 ng/mL recombinant mouse Fms-related tyrosine kinase three ligand (Flt3-Ligand, Miltenyi Biotec) at 37°C in a humid atmosphere. M1 MΦ were obtained by culturing cells in 1 g/L glucose DMEM (Sigma) supplied with 15% FCS, 1 µg/mL P/S, 2 mM Gln (Sigma), 100 ng/mL LPS (Sigma) and 10 U/mL recombinant mouse IFNγ (eBioscience). M2 MΦ were obtained by culturing cells with 1g/L glucose DMEM supplemented with 15% FCS, 1% P/S, 2mM Gln (Sigma) and 50 ng/mL recombinant mouse IL4 (Miltenyi Biotec).

Cell and hypoxic cultures

The normoxic state (20% O₂) was a humidified 5% CO₂/air atmosphere in an incubator and hypoxia was obtained with a humidified 5% CO₂/balance N₂ gas mixture in a hypoxic chamber (Invivo2 500, Ruskinn, Awel) at 37°C. For the polarization experiments, M0 MΦ were cultured either in normoxia or in hypoxia (1% or 0.2% O₂) for different time periods. For the re-education experiments, M1 and M2 MΦ were activated 24 h and then cultured in hypoxia (1% or 0.2% O₂) with their respective conditioning media for different time periods. GBM cell lines were cultured in the M0 MΦ growth medium, as described above, in normoxia or in 1% or 0.2% O₂ for 24 h.

Reverse transcription and real-time quantitative PCR

Total RNA was isolated by the Nucleospin® RNA kit (Macherey-Nagel) following manufacturer’s instructions and reverse transcribed into cDNA (cDNA) with AMV® reverse transcriptase (Promega). cDNA were then quantified by real-time PCR with SYBR® Green master mix (Bio-Rad) with primers designed by Eurogentec (Table S2). Samples were run in triplicate with an amplification profile as follows: an activation stage at 95°C for 3 min following by 40 cycles at 95°C, 15 sec and 60°C, 30 sec. Expression levels were determined by the ΔCt method.

Determination of nitric oxide (NO) production

NO measurement in the SN of MΦ cultures was performed by the Griess reaction. Briefly, the Griess reagent was prepared by mixing 2% sulphanilamide (Sigma) in 10% phosphoric acid (Sigma) and 0.2% naphthylethylene-diamine-dihydrochloride (Sigma). The reagent was added to SN and the mixture was incubated 10 min at room temperature in the dark. Each sample was assayed in duplicate, the absorbance was measured at 540 nm and NO concentration was determined with sodium nitrite as a standard.

Determination of Arg1 activity

Arg1 activity was determined by a standard colorimetric method in cell lysates. Briefly, cells were lysed by adding 0.1% Triton X-100 (Sigma) and 50 mM Tris–HCl (pH 7.5). 10 mM MnCl₂ (Sigma) to cell samples, then heated at 56°C for 7 min to activate the enzyme. Hydrolysis of L-arginine by Arg1 was performed by incubating the mixture with 50 µmol of L-arginine (pH 9.7; Sigma) at 37°C for 2 h, and the reaction was stopped by adding an acid solution (H₂SO₄; H₃PO₄; H₂O). For the determination of urea production, α-ionitrosopropiophenone (Sigma) was added and the mixture was incubated at 95°C for 30 min and then 4°C for 30 min. Each sample was assayed in duplicate, the absorbance was measured at 540 nm and urea production was determined with urea as a standard.

Statistical analyses

All data are presented as the mean ± standard deviation (SD). Statistical analyses were performed with the JMP® program (SAS institute, USA) and, unless otherwise stated, significances were calculated by nonparametric Kruskall–Wallis for multiple comparisons or Mann–Whitney U tests. Statistical significance was achieved when p < 0.05 (*) or p < 0.01 (**), otherwise they were not significant (NS).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgements

The authors wish to thank the LDM-TEP team for the [¹⁸F]-FMISO production.

Funding

This study was supported by the grants from the Conseil Régional de Basse-Normandie, the Université de Caen Basse-Normandie (UCBN), the French Ministère de l’Enseignement Supérieur et de la Recherche (MESR), the Center National de la Recherche Scientifique (CNRS), the TC2N ‘Trans Channel Neuroscience Network’ Interreg IV A 2 Mers Seas Zeéens program, “Investing in your future” crossborder cooperation program 2007–2014 part financed by the European Union (European Regional Development Fund), the French National Agency for Research called “Investissements d’Avenir” no. ANR-11-LABEX-0018-01, the Fédération pour la Recherche sur le Cerveau (FRC), the Institut National contre le Cancer (INCa), and the Advanced Resource Center for Hadrontherapy in Europe (Archade).

Supplemental Material

Supplemental data for this article can be accessed on the publisher’s website.
42. Leek RD, Tstalk KL, Pezzella F, Turlcy H, Campo L, Brown NS, Bicknell R, Taylor M, Gatter KC, Harris AL. Relation of hypoxia-inducible factor-2α (HIF-2α) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res 2002; 62:1126-9; PMID:1188900

43. Burke B, Giannoudis A, Corke KP, Gill D, Wells M, Ziegler-Heitbrock L, Lewis CE. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol 2003; 163:1233-43; PMID:14507633; http://dx.doi.org/10.1016/S0002-9440(10)63483-9

44. Fang H-Y, Hughes R, Murdoch C, Coffelt SB, Biswas SK, Harris AL, Johnson RS, Imityaz HZ, Simon MC, Karin M, Coussens LM, Goldrath AW, Johnson RS. Macrophage expression of HIF-1α suppresses T cell function and promotes tumor progression. Cancer Res 2010; 70:7465-75; PMID:20841473; http://dx.doi.org/10.1158/0008-5472.CAN-10-1439

45. Koh MY, Powis G. Passing the baton: the HIF switch. Trends Biochem Sci 2012; 37:364-72; PMID:22818162; http://dx.doi.org/10.1016/j.tibs.2012.06.004

46. Sontxavaux P, Veygann F, Schroer T, Wergin MC, Ver- rass J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Gaty B, Jordan BF et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008; 118:3930-42; PMID:19033663; http://dx.doi.org/10.1172/JCI36843

47. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezvral J, Sattoussou M, Martin JD, Martin MR, Vianello F et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2013; 109:17561-6; PMID:23945683; http://dx.doi.org/10.1073/pnas.1215397109

48. Miranda-Goncalves V, Honavar M, Pinheiro C, Martinho O, Pires MM, Pinheiro C, Cordeiro M, Belfio G, Costa P, Palmeritim I et al. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro Oncol 2013; 15:172-88; PMID:23258846; http://dx.doi.org/10.1093/neuonc/nos298

49. Stout RD, Jiang C, Carta B, Tietz I, Watkins SK, Surtels J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005; 175:342-9; PMID:15972667; http://dx.doi.org/10.4049/jimmunol.175.1.342

50. Dehne N, Tausendschon M, Esler S, Geis T, Schmid T, Brüne B. IL-4 reduces the proangiogenic capacity of macrophages by down-regulating HIF-1α translation. J Leukoc Biol 2014; 95:129-37; PMID:24086507; http://dx.doi.org/10.1189/jlb.03110645

51. Goodman JE, Hofscher LJ, Hussain SP, Harris CC. Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environ Mol Mutagen 2004; 44:3-9; PMID:15199542; http://dx.doi.org/10.1002/em.20024

52. Weigert A, Brüne B. Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric Oxide 2010; 20:195-102; PMID:18486631; http://dx.doi.org/10.1016/j.niox.2008.04.021

53. Singh S, Gupta AK. Nitric oxide: role in tumor biology and iNOS/NO-based anticancer therapies. Cancer Chemother Pharmacol 2011; 67:1211-24; PMID:21544630; http://dx.doi.org/10.1007/s00280-011-1654-4

54. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Ballow FR. “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008; 205:1261-8; PMID:18490490; http://dx.doi.org/10.1084/jem.20080108

55. Buhtsiev OA, Wrigley JD, Wrigley JD, Martin JD, Martin MR, Vianello F et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2012; 109:17561-6; PMID:23945683; http://dx.doi.org/10.1073/pnas.1215397109

56. Garris C, Peter MJ. Therapeutically reeducating macrophages to treat GBM. Nat Med 2013; 19:1207-8; PMID:24100977; http://dx.doi.org/10.1038/nm.3355

57. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezvral J, Sattoussou M, Martin JD, Martin MR, Vianello F et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2012; 109:17561-6; PMID:23945683; http://dx.doi.org/10.1073/pnas.1215397109

58. Stuhr LEB, Raa A, Oyan AM, Kalland KH, Sakariassen PO, Petersen K, Bjerkevig R, Reed RK. Hypoxia retards growth and induces apoptosis, changes in vascular density and gene expression in transplanted gliomas in nude rats. J Neurooncol 2007; 85:191-202; PMID:17571737; http://dx.doi.org/10.1007/s10937-007-9407-2

59. Reiner NE, editor. Macrophages and Dendritic Cells: Methods and Protocols. New York, NY: Humana Press; 2009.